IL325831A - Formulations of rock2 inhibitors for cns disorders - Google Patents

Formulations of rock2 inhibitors for cns disorders

Info

Publication number
IL325831A
IL325831A IL325831A IL32583126A IL325831A IL 325831 A IL325831 A IL 325831A IL 325831 A IL325831 A IL 325831A IL 32583126 A IL32583126 A IL 32583126A IL 325831 A IL325831 A IL 325831A
Authority
IL
Israel
Prior art keywords
formulations
cns disorders
rock2 inhibitors
rock2
inhibitors
Prior art date
Application number
IL325831A
Other languages
Hebrew (he)
Original Assignee
Graviton Bioscience Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Graviton Bioscience Bv filed Critical Graviton Bioscience Bv
Publication of IL325831A publication Critical patent/IL325831A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL325831A 2023-07-17 2024-07-17 Formulations of rock2 inhibitors for cns disorders IL325831A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363514042P 2023-07-17 2023-07-17
PCT/IB2024/056936 WO2025017500A1 (en) 2023-07-17 2024-07-17 Formulations of rock2 inhibitors for cns disorders

Publications (1)

Publication Number Publication Date
IL325831A true IL325831A (en) 2026-03-01

Family

ID=92302638

Family Applications (1)

Application Number Title Priority Date Filing Date
IL325831A IL325831A (en) 2023-07-17 2024-07-17 Formulations of rock2 inhibitors for cns disorders

Country Status (3)

Country Link
AU (1) AU2024294840A1 (en)
IL (1) IL325831A (en)
WO (1) WO2025017500A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026053168A1 (en) * 2024-09-06 2026-03-12 Graviton Bioscience Bv Amorphous forms of a rock2 inhibitor and formulations thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4201178C2 (en) 1992-01-17 1995-12-07 Alfatec Pharma Gmbh Process for the production of soft gelatin capsules by a dropping process
NL1009107C2 (en) 1997-11-12 1999-06-15 Banner Pharmacaps Inc Extrusion device for forming multi layer gelatine films used to form soft gel capsules - contains two height adjustable gate valves covering nozzle opening to control thickness of the individual extruded gelatine film layers
IL142819A0 (en) 1998-11-11 2002-03-10 Bioprogress Tech Int Inc A capsule based drug delivery system
US6340473B1 (en) 1999-07-07 2002-01-22 R.P. Scherer Technologies, Inc. Film forming compositions comprising modified starches and iota-carrageenan and methods for manufacturing soft capsules using same
US10857157B2 (en) * 2015-01-26 2020-12-08 BioAxone BioSciences, Inc. Treatment of cerebral cavernous malformations and cerebral aneurysms with rho kinase inhibitors
AU2018294054B2 (en) 2017-06-30 2022-05-26 Beijing Tide Pharmaceutical Co., Ltd. Rho-associated protein kinase inhibitor, pharmaceutical composition comprising same, and preparation method and use thereof
CN110573501B (en) 2017-06-30 2023-09-29 北京泰德制药股份有限公司 Rho-related protein kinase inhibitors, pharmaceutical compositions containing the same and preparation methods and uses thereof
WO2019000683A1 (en) 2017-06-30 2019-01-03 北京泰德制药股份有限公司 Rho-associated protein kinase inhibitor, pharmaceutical composition containing rho-associated protein kinase inhibitor, preparation method and use of the pharmaceutical composition
EA202090306A1 (en) * 2017-07-21 2020-06-25 Кадмон Корпорейшн, Ллк INHIBITORS OF RHO-ASSOCIATED CONTAINING SUPERSPIRAL PROTEINKINASE
US12398118B2 (en) 2018-11-09 2025-08-26 Beijing Tide Pharmaceutical Co., Ltd. Rho-associated protein kinase inhibitor, pharmaceutical composition comprising same, and use thereof
KR102906316B1 (en) 2019-03-01 2025-12-31 베이징 타이드 파마슈티컬 코퍼레이션 리미티드 Treatment of fatty liver disease and/or steatohepatitis
CA3144113A1 (en) 2019-06-25 2020-12-30 Beijing Tide Pharmaceutical Co., Ltd. Method for treating idiopathic pulmonary fibrosis
KR20230058466A (en) 2020-08-31 2023-05-03 베이징 타이드 파마슈티컬 코퍼레이션 리미티드 Methods for preparing novel RHO-associated protein kinase inhibitors and intermediates in manufacturing methods
CN118772118A (en) * 2020-08-31 2024-10-15 北京泰德制药股份有限公司 Salts of Rho-associated protein kinase inhibitors, solid forms thereof, and preparation methods and uses thereof
US20250352543A1 (en) * 2021-11-16 2025-11-20 Beijing Tide Pharmaceutical Co., Ltd. Nanocrystalline preparation of rock2 inhibitor and preparation method therefor

Also Published As

Publication number Publication date
AU2024294840A1 (en) 2026-02-26
WO2025017500A1 (en) 2025-01-23

Similar Documents

Publication Publication Date Title
IL320739A (en) Inhibitors of rock2
IL295364B1 (en) Psilocin derivatives as serotonergic psychedelic agents for the treatment of cns disorders
IL316616A (en) Inhibitors of rock2
IL315722A (en) Piperazine substituted indazole compounds as inhibitors of parg
EP4100403A4 (en) 3-pyrrolidine-indole derivatives as serotonergic psychedelic agents for the treatment of cns disorders
ZA202212146B (en) Inhibitors of nek7 kinase
JOP20230170A1 (en) CDK2 inhibitors and methods for using them
IL314308A (en) Ubiquitin-specific-processing protease 1 (usp1) inhibitors for the treatment of solid tumors
IL325528A (en) Use of glycerides for lnp formulations
IL325596A (en) Pharmaceutical compositions for inhibitors of nek7 kinase
CA3298108A1 (en) Formulations of rock2 inhibitors for cns disorders
IL319571A (en) R-trihexyphenidyl for treatment of movement disorders
IL325832A (en) Formulations and uses of rock2 inhibitors for als
IL307382A (en) Therapeutic inhibitors of gdf15 signalling
EP4153616A4 (en) Compositions and methods for treatment of inflammatory disorders
EP4100065A4 (en) Use of mirna-485 inhibitors for treating tauopathy
GB202201708D0 (en) Compositions for oral delivery of biotherapeutics
CA3273444A1 (en) Inhibitors of rock2
HK40122640A (en) Inhibitors of rock2
TWI926416B (en) Inhibitor compounds for selective passivation of surfaces
HK40076349A (en) Allogeneic composition for treatment of cns disorders
HK40082254A (en) Compounds and compositions for treating cns disorders
HK40082232A (en) Compounds and compositions for treating cns disorders
IL317760A (en) Benzocarbazole derivatives as inhibitors of drp1
CA3297265A1 (en) Pharmaceutical compositions for inhibitors of nek7 kinase